Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Therapeutic Innovation & Regulatory Science|December 10, 2020
Development and Validation of a Brief Measure of Self-Management Competence: The Self-Management Self-Test (SMST)Peter M Wehmeier, Theresa Fox, Johanna M Doerr, et al.Therapeutic Innovation & Regulatory Science|July 16, 2019
Development and Validation of a Brief Measure of Self-Management Competence: The Self-Management Self-Test (SMST)Peter M Wehmeier, Theresa Fox, Johanna M Doerr, et al.Journal of Child and Adolescent Psychopharmacology|November 2, 2011
Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking devicePeter M Wehmeier, Alexander Schacht, Christian Wolff, et al.Child and Adolescent Psychiatry and Mental Health|August 26, 2009
Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physiciansRalf W Dittmann, Peter M Wehmeier, Alexander Schacht, et al.Journal of Child and Adolescent Psychopharmacology|March 5, 2008
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label studyPeter M Wehmeier, Ralf W Dittmann, Alexander Schacht, et al.Child and Adolescent Psychiatry and Mental Health|May 30, 2008
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)Peter M Wehmeier, Alexander Schacht, Martin Lehmann, et al.Journal of Psychiatric Research|August 28, 2007
Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophreniaPeter M Wehmeier, Michael Kluge, Alexander Schacht, et al.Journal of Child and Adolescent Psychopharmacology|April 15, 2011
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in GermanyRalf W Dittmann, Alexander Schacht, Karin Helsberg, et al.Journal of Clinical Psychopharmacology|August 29, 2012
Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technologyPeter M Wehmeier, Alexander Schacht, Fredrik Ulberstad, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 8, 2010
Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorderPeter M Wehmeier, Alexander Schacht, Ralf W Dittmann, et al.Pageof 4